fullerene c60 has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Han, Z; Lu, ZR; Roelle, S; Schiemann, WP; Wu, X | 1 |
| Bai, R; Chen, C; Chen, Z; Dong, J; Gao, X; Li, H; Liu, S; Liu, Y; Lobie, PE; Lu, X; Qian, P; Sun, B; Tang, J; Wang, L; Wicha, MS; Wu, Q; Zhang, H; Zhang, W; Zhang, X; Zhao, F; Zhao, Y; Zhu, T | 1 |
2 other study(ies) available for fullerene c60 and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Female; Fullerenes; Gadolinium; Humans; Magnetic Resonance Imaging; MCF-7 Cells; Mice; Precision Medicine; Triple Negative Breast Neoplasms | 2017 |
Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor.
Topics: Animals; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Female; Fullerenes; Gadolinium; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Nanomedicine; Nanostructures; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Transforming Growth Factor beta; Triple Negative Breast Neoplasms | 2015 |